
Sahajanand Medical Technologies IPO: Listing Price, Subscription Status, Allotment & Dates
BSE/NSE · Mainboard
Sahajanand Medical Technologies IPO at a glance
- Opens
- 15 Oct 2026
- Closes
- 19 Oct 2026
- Allotment
- 21 Oct 2026
- Listing
- 23 Oct 2026 · BSE/NSE
- Price band
- ₹327 – ₹344
- Lot size
- 43 shares (min ₹14,792)
- Issue size
- ₹475 Cr
- Registrar
- MUFG Intime India Pvt Ltd
Subscription: QIB 34.7x · NII 14.64x · Retail 3.04x · Total 14.21x (as of 16 Nov 2026, 9:00 PM IST)
GMP: ₹17 (4.94% of upper band) · estimated listing price ₹361 (updated 16 Nov 2026, 9:00 PM IST)
GMP is unofficial grey-market data and the listing estimate is simply upper band + GMP — not a prediction or advice.
Price Band
₹327 - ₹344
Lot Size
43 shares
Min ₹14,792
Issue Size
₹475 Cr
GMP (Grey Market)
₹17
4.9% premium
Important Dates
Open Date
15 Oct 2026
Close Date
19 Oct 2026
Allotment
21 Oct 2026
Listing
23 Oct 2026
Subscription Status
Day-by-Day Subscription
| Day | QIB | NII | Retail | Employee | Total |
|---|---|---|---|---|---|
| Day 1 (20 Oct 2026) | 34.70x | 14.64x | 3.04x | 0.37x | 14.21x |
| Day 2 (21 Oct 2026) | 34.70x | 14.64x | 3.04x | 0.37x | 14.21x |
| Day 3 (22 Oct 2026) | 34.70x | 14.64x | 3.04x | 0.37x | 14.21x |
| Day 4 (23 Oct 2026) | 34.70x | 14.64x | 3.04x | 0.37x | 14.21x |
GMP History
| Date | GMP (₹) | GMP (%) |
|---|---|---|
| 11 Oct 2026 | ₹35 | — |
| 12 Oct 2026 | ₹40 | 11.6% |
| 13 Oct 2026 | ₹37 | 10.8% |
| 14 Oct 2026 | ₹38 | 11.1% |
| 15 Oct 2026 | ₹42 | 12.2% |
| 16 Oct 2026 | ₹38 | 11.1% |
| 17 Oct 2026 | ₹15 | 4.4% |
| 18 Oct 2026 | ₹29 | 8.4% |
| 19 Oct 2026 | ₹24 | 7.0% |
| 20 Oct 2026 | ₹25 | 7.3% |
| 21 Oct 2026 | ₹24 | 7.0% |
| 22 Oct 2026 | ₹16 | 4.7% |
| 23 Oct 2026 | ₹17 | 4.9% |
| 24 Oct 2026 | ₹17 | 4.9% |
| 25 Oct 2026 | ₹17 | 4.9% |
| 26 Oct 2026 | ₹17 | 4.9% |
| 27 Oct 2026 | ₹17 | 4.9% |
| 28 Oct 2026 | ₹17 | 4.9% |
| 29 Oct 2026 | ₹17 | 4.9% |
| 30 Oct 2026 | ₹17 | 4.9% |
| 31 Oct 2026 | ₹17 | 4.9% |
| 1 Nov 2026 | ₹17 | 4.9% |
| 2 Nov 2026 | ₹17 | 4.9% |
| 3 Nov 2026 | ₹17 | 4.9% |
| 4 Nov 2026 | ₹17 | 4.9% |
| 5 Nov 2026 | ₹17 | 4.9% |
| 6 Nov 2026 | ₹17 | 4.9% |
| 14 Nov 2026 | ₹17 | 4.9% |
| 15 Nov 2026 | ₹17 | 4.9% |
| 16 Nov 2026 | ₹17 | 4.9% |
Sahajanand Medical Technologies IPO allotment status
The basis of allotment is expected on 21 Oct 2026. The registrar to the issue is MUFG Intime India Pvt Ltd. Once allotment is final, shares are credited to your demat account before listing, and the blocked amount is released if you are not allotted.
Sahajanand Medical Technologies IPO listing date
Sahajanand Medical Technologies listed on 23 Oct 2026 on BSE/NSE. It listed at ₹371.15, +7.9% versus the ₹344 upper band.
Financial Performance
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 901.6 | 1,024.88 | 1,210.5 |
| Profit (₹ Cr) | -7.35 | 25.15 | 69.08 |
| Total Assets (₹ Cr) | 970.58 | 1,094.9 | 1,276.43 |
As disclosed by Sahajanand Medical Technologies in its offer document.
Strengths and risks
Taken from Sahajanand Medical Technologies's own offer document — not Arthneeti's assessment.
- ✓According to the F&S Report, Sahajanand Medical Technologies held nearly 25% of India's drug-eluting stents (DES) market by sales volume in FY26. The company was also among the top five by DES sales volume in Germany, Spain, Poland, and Brazil as of March 31, 2026.
- !The company's revenue from vascular intervention (VI) devices stood at Rs 618.27 crore (68.57%), Rs 674.97 crore (65.86%), and Rs 740.09 crore (61.14%) in FY24, FY25, and FY26, respectively. Additionally, its Supraflex Cruz product contributed Rs 431.35 crore (47.84%), Rs 431.03 crore (42.06%), and Rs 450.00 crore (37.17%) to revenue from operations during the same periods, respectively. Any decline in demand for these products or increased competition could adversely affect the company's revenue and profitability.
- ✓The company marketed its products in 77 countries, including India, in FY26. Its international revenue from operations increased from Rs 587.84 crore in FY24 to Rs 704.23 crore in FY25 and Rs 894.20 crore in FY26, representing a CAGR of 23.34%.
- !The company's top 10 suppliers accounted for purchases worth Rs 164.57 crore (58.88%), Rs 170.75 crore (64.37%), and Rs 184.72 crore (59.15%) in FY24, FY25, and FY26, respectively. The company also depends on a limited number of suppliers, including single suppliers for certain critical materials, and does not enter into long-term supply agreements. Any supply disruption or increase in raw material prices could adversely affect its manufacturing operations and profitability.
17 more points from Sahajanand Medical Technologies's offer document
About Sahajanand Medical Technologies
Sahajanand Medical Technologies Limited develops, manufactures, and sells medical devices used in vascular and structural heart interventions. Founded in 2001, the company offers vascular intervention products, including coronary stents and coronary balloon catheters, and structural heart products, including transcatheter aortic valve implantation (TAVI) devices and occluders. Its portfolio also includes renal stents, peripheral drug-coated balloons, and traded medical products. The company markets its products through direct sales, hybrid, and distributor-led models. In FY26, it generated revenue from 77 countries, including India, with operations across Europe and other international markets. It currently operates three manufacturing facilities, two in India and one in Thailand. Additionally, it has two research and development centres, located in India and Thailand, focused on medical device development and product improvements. Use of proceeds: The IPO is an offer-for-sale (OFS). The company will not receive any proceeds from the offer. Net proceeds from the offer will go to the promoter selling shareholders in proportion to the number of shares offered by them for sale. The primary objective of the offer is to achieve the benefits of listing the equity shares on the stock exchanges, which is expected to enhance the company’s visibility and brand recognition. Listing will also provide liquidity to the existing shareholders and create a public market for the company’s shares in India.
Research the Healthcare sector
See how Healthcare companies rank on Arthneeti's AI earnings-call scorecard.
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
GMP data is indicative and sourced from grey market. Subscription data is from exchange filings. This is not investment advice. Please consult a SEBI-registered advisor before investing.